Zhi Tong Cai Jing·2025-11-14 12:17Group 1 - Merck (MRK.US) has reached a definitive agreement to acquire Cidara Therapeutics (CDTX.US) for $221.50 per share in cash, totaling approximately $9.2 billion [1] - Cidara's stock surged over 100% in pre-market trading, reaching $216.13, reflecting strong market reaction to the acquisition news [1] - Cidara's lead candidate, CD388, is an investigational long-acting antiviral drug currently in Phase 3 clinical trials, aimed at preventing influenza infections in high-risk populations [1] Group 2 - The acquisition is expected to enhance Merck's respiratory product portfolio and research pipeline, according to Dr. D. Lee, President of Merck Research Laboratories [1] - The transaction has been approved by the boards of both companies but is subject to HSR approval and other customary closing conditions [1] - The deal is anticipated to close in the first quarter of 2026 [2]